

# Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors


This update of the 2013 guideline will help ensure:



- Uniform approach to molecular testing
- Improved effectiveness of treatment for patients

**2nd**  
Most common cancer in both



**1:15** Develop lung cancer in a lifetime  
**1:17**



**26%**  **25%**   
Die of lung cancer

## New Evidence-based Recommendations:

- Patients with certain biomarkers can benefit from targeted therapy
- *EGFR*, *ALK*, and *ROS1* testing must be performed on all advance stage lung cancer patients



Review all of the new and updated recommendations



COLLEGE of AMERICAN  
PATHOLOGISTS

IASLC  
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER



AMP  
ASSOCIATION  
FOR MOLECULAR  
PATHOLOGY

Lindeman NI, Cagle PT, Aisner DL et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *Arch Pathol Lab Med.* 2018;142(3):321-346. doi: 10.5858/arpa.2017-0388-CP

American Cancer Society. Key Statistics for Lung Cancer. American Cancer Society website. <https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html> Updated January 4, 2018. Accessed January 11, 2018.

© 2018 CAP, IASLC, AMP. All rights reserved.  
26340.0118

cap.org